Digoxin is associated with increased risk of death in heart failure patients treated with beta-blockers. Results from Polish part of ESC HF Long-Term Registry.

CONCLUSIONS: Digoxin is associated with increased risk of death in HFrEF patients without AF history receiving the guideline-directed treatment. It seems to be employed in patients with worse clinical status, which may be at least partially responsible for its association with increased risk of death.
PMID: 29476617 [PubMed - as supplied by publisher]

Source: Polish Heart Journal - February 24, 2018 Category: Cardiology Authors: Migaj J, Kałużna-Oleksy M, Nessler J, Opolski G, Crespo-Leiro M, Maggioni AP, Grajek S, Ponikowski P, Drożdż J, Straburzyńska-Migaj E Tags: Kardiol Pol Source Type: research